Charles River Laboratories | CRL - Gewinn Vor Steuern

Aktienkurs
166.97
Täglich Wechseln
3.13 1.91%
Monatlich
-3.21%
Jährlich
42.84%
Q2 Prognose
166.17




Gewinn Vor Steuern Veränderung Datum
Agilent USD 442M 1000K 2025-09
Align Technology USD 148.89M 27.71M 2026-03
Bio-Rad Laboratories USD 929.2M 846.3M 2025-12
Bruker USD -72.6M 73.1M 2025-09
Cardinal Health USD 630M 32M 2025-12
Charles River Laboratories USD 170.03M 98.62M 2025-09
Cigna USD 1.82B 478M 2025-12
CVS Health USD 1.35B 4.84B 2025-12
Danaher USD 1.24B 138M 2026-03
Dentsply International USD -230M 77M 2025-09
Elevance Health USD 215M 1.19B 2025-12
Galapagos EUR -221.49M 117.07M 2025-09
Humana USD -1.01B 1.54B 2025-12
Illumina USD 377M 157M 2025-12
Incyte USD 389.94M 92.37M 2025-12
Intrexon USD -60.48M 27.09M 2024-06
IQVIA Holdings USD 537M 5.62B 2025-12
Laboratory Of America USD 190.6M 146.4M 2025-12
Lonza CHF 624M 197M 2024-12
McKesson USD 1.4B 344M 2025-09
Merck EUR 1.29B 458.1M 2025-09
Mettler Toledo International USD 269.24M 20.58M 2025-09
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
Quest Diagnostics USD 334M 4M 2026-03
Revvity USD 55.68M 115.97M 2025-09
Thermo Fisher Scientific USD 2.12B 295M 2025-12
United Therapeutics USD 444M 6M 2025-12
UnitedHealth USD -720M 3.95B 2025-12
Veradigm USD 35.3M 13.95M 2022-09
Waters USD 170.12M 7.57M 2025-09
West Pharmaceutical Services USD 161.5M 8.6M 2025-12